Select a community
ALS including PLS and PMA
Find out more about the PatientsLikeMe
ALS Community
Home > Community Treatment Reports > Ambien CR (zolpidem) Treatment Report
What is Ambien CR?

Ambien CRâ„¢ is a brand name for the extended release form of zolpidem. It is a sedative-hypnotic drug used for short-term treatment of insomnia that presents as difficulty of sleep onset and maintenance of sleep.

Reasons taken & Efficacy

Reasons and Efficacy
Reasons taken # of patients Major Moderate Slight None Can’t tell # of patients evaluated by
Insomnia 16 3
Other 1 0

Mouse over the table for more information

Side Effects

Side effects as an overall problem

Severe
0 0%
Moderate
0 0%
Mild
0 0%
None
3 100%

Dosages

  10mg as needed 12.5mg as needed 5 mg daily 6.25 mg daily 10 mg daily 12 mg daily 12.5 daily 12.5 mg daily
  1 Number of Patients: 1 1 Number of Patients: 1 1 Number of Patients: 1 3 Number of Patients: 3 1 Number of Patients: 1 1 Number of Patients: 1 1 Number of Patients: 1 9 Number of Patients: 9  

Stop Reasons

Why Patients Stopped Taking Ambien CR (multiple reasons could be selected)
Reason # Patients Percentage of patients
Expense
1 25% Expense: 25%
Doctor's advice
1 25% Doctor's advice: 25%
Other
1 25% Other: 25%
Course of treatment ended
1 25% Course of treatment ended: 25%

See all 4 patients who’ve stopped taking Ambien CR

Currently Taking Ambien CR

0-1 month 1-3 months 3-6 months 6 months-1year 1-2 years 2 years or more
0
0
1
5
1
5

Stopped Taking Ambien CR

0-1 month 1-3 months 3-6 months 6 months-1year 1-2 years 2 years or more
0
2
1
1
0
0

Adherence, Burden & Cost See details from patient evaluations

Adherence

Taking treatment as prescribed

Always
2 67%
Usually
1 33%
Sometimes
0 0%
Never
0 0%

Burden

Difficulty being on treatment

Very
0 0%
Somewhat
0 0%
A little
0 0%
Not at all
3 100%

Cost

Paid out of pocket

$200+
0 0%
$100-199
0 0%
$50-99
0 0%
$25-49
1 33%
< $25
2 67%

See more information, including instructions, precautions, side effects, and interactions.

Report created on November 22, 2009.